Elissa Goodman

Elissa Goodman supports the Centers for Disease Control and Prevention’s Office of Acquisition Services in managing critical procurement activities that enable public health surveillance, laboratory diagnostics, and biomedical research operations. She plays a key role in executing complex acquisitions for scientific and technical services, analytical instrumentation, and specialized chemical manufacturing essential to CDC’s mission of detecting and responding to infectious disease threats. Her work ensures timely access to high-capacity laboratory systems, diagnostic tools, and research infrastructure, aligning procurement decisions with national health security priorities and scientific innovation goals. Goodman maintains longstanding relationships with leading contractors including General Dynamics Information Technology, GlaxoSmithKline, New York City Health & Hospitals Corp, MRIGLOBAL, and Cepheid. These partnerships reflect a focus on high-reliability vendors capable of delivering mission-critical diagnostics, biomedical reagents, and large-scale public health operational support. Her contracting approach emphasizes performance-based outcomes, technical compliance, and supply chain resilience, often involving multi-year, performance-driven task orders and delivery orders under IDIQ vehicles. Goodman’s procurement portfolio shows no reliance on socioeconomic set-asides, with 100% of awards issued under full and open competition. This reflects a strategic emphasis on technical capability and operational readiness over socioeconomic preferences, prioritizing the most qualified entities capable of meeting stringent public health response requirements. While small business participation is not formally targeted, all procurements adhere to federal transparency and fair competition standards. Her primary procurement focus lies in NAICS 541990 for professional scientific services, 325199 for organic chemical manufacturing, and 334516 for analytical laboratory instrument manufacturing. These categories underscore her expertise in acquiring advanced diagnostic platforms, research-grade reagents, and precision instrumentation used in CDC’s national laboratories and field epidemiology units, ensuring the agency maintains cutting-edge capacity for pathogen detection and public health analytics.